Purpose To study the effect of sildenafil, which is an effective agent for the treatment of erectile dysfunction, on ocular haemodynamics. 
Study design
A single oral dose of 50 mg sildenafil was administered to 14 healthy male volunteers. The following tests were performed on both eyes immediately before and 1 h after sildenafil administration: visual acuity, lOP (Goldmann applanation tonometry), colour vision, anterior segment, fundus appearance, resting heart rate, blood pressure and colour Doppler measurements. The maximum effect of single dose administration has been reported to be at 1 h for sildenafil.
1 3 Therefore, 1 h after sildenafil 
Statistical analysis included a Wilcoxon rank-sum test. A p value of less than 0.05 was considered statistically Significant. Table 1 ). However, heart rate increased significantly after sildenafil administration compared with baseline (p < 0.05, Table 1 ). Tables 2--4 show PSV, EDV, MV, RI and PI in the CRA, OA and STPCA calculated at baseline and after sildenafil administration. After sildenafil administration PSV, EDV and MV significantly increased in the OA of both eyes (p < 0.05, Table 2 ). All Doppler indices remained non significant for CRA and STPCA of both eyes (p > 0.05, Tables 3, 4) .
Results

There was no
Discussion
Sildenafil is a highly selective inhibitor of PDE5, responsible for the breakdown of cGMP in the corpus cavernosum. 14 -1 6 Inhibition of cGMP degradation allows for normal penile erection by the NO-cGMP-mediated relaxation pathway. PSV, peak systolic velocity; EDV, end-diastolic velocity; MV, mean velocity; RI, resistance index; PI, pulsatility index. However, a significant increase in heart rate was showed that L-arginine, an inhibitor of NO synthase, decreased mean flow velocity in the OA in healthy subjects. The results of our study confirm this finding.
On the basis of these findings we propose that increased flow velOcity may be due to the vasodilatory effect of sildenafil.
Limitations of this study include the relatively small number of subjects and the lack of a control group for comparison. Nevertheless, our study shows that oral sildenafil increased ophthalmic artery systolic, diastolic and mean blood flow velocity in healthy male volunteers.
The significance of this remains to be determined. As more information becomes available about the effect of sildenafil on the retinal circulation we may need to consider situations in which the medicine may be beneficial or detrimental to the retinal and/ or optic nerve head circulations. Conditions in which retinal ischaemia is present may benefit from the medication. The effect of increased flow on retinal oedema will also need to be evaluated. The same considerations may need to be taken into account when using systemic medications which are known to be vasodilators.
More extensive and controlled studies are necessary to clarify the mode of action of sildenafil on retinal function and ocular circulation and to study the long term effects of the drug in patients with retinal diseases.
